Assembly Biosciences (NASDAQ:ASMB – Get Free Report) is one of 897 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Assembly Biosciences to similar companies based on the strength of its dividends, valuation, earnings, risk, analyst recommendations, institutional ownership and profitability.
Profitability
This table compares Assembly Biosciences and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Assembly Biosciences | -0.06% | -0.02% | -0.02% |
| Assembly Biosciences Competitors | -2,380.90% | -221.90% | -15.99% |
Valuation and Earnings
This table compares Assembly Biosciences and its competitors revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Assembly Biosciences | $72.30 million | -$6.12 million | 19.74 |
| Assembly Biosciences Competitors | $3.55 billion | $3.19 billion | 547.84 |
Assembly Biosciences’ competitors have higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
Assembly Biosciences has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, Assembly Biosciences’ competitors have a beta of -3.75, suggesting that their average share price is 475% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current recommendations for Assembly Biosciences and its competitors, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Assembly Biosciences | 1 | 0 | 4 | 1 | 2.83 |
| Assembly Biosciences Competitors | 7765 | 13847 | 25696 | 1031 | 2.41 |
Assembly Biosciences presently has a consensus price target of $47.50, suggesting a potential upside of 135.97%. As a group, “Pharmaceuticals” companies have a potential upside of 24.30%. Given Assembly Biosciences’ stronger consensus rating and higher probable upside, research analysts plainly believe Assembly Biosciences is more favorable than its competitors.
Insider & Institutional Ownership
19.9% of Assembly Biosciences shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 3.5% of Assembly Biosciences shares are held by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Assembly Biosciences beats its competitors on 8 of the 13 factors compared.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
